Pfizer (PFE) Inventory Average (2009 - 2026)

Pfizer (PFE) has 18 years of Inventory Average data on file, last reported at $10.7 billion in Q1 2026.

• Quarterly Inventory Average fell 1.76% year-over-year to $10.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.7 billion (down 1.76% YoY) and the FY2025 annual result came in at $10.8 billion, down 4.73% from the prior year.
• Inventory Average slipped to $10.7 billion in Q1 2026 per PFE's latest filing, from $11.1 billion in the prior quarter.
• Across five years, Inventory Average topped out at $11.6 billion in Q3 2024 and bottomed at $9.2 billion in Q4 2022.
• The 5-year median for Inventory Average is $10.5 billion (2024), against an average of $10.5 billion.
• The widest annual swing landed in 2022, when Inventory Average climbed 17.15%; it then retreated 2.85% in 2023.
• Tracing PFE's Inventory Average over 5 years: stood at $9.2 billion in 2022, then climbed by 10.27% to $10.2 billion in 2023, then climbed by 10.69% to $11.3 billion in 2024, then slipped by 1.99% to $11.1 billion in 2025, then decreased by 3.62% to $10.7 billion in 2026.
• Per Business Quant, the three latest PFE Inventory Average figures stand at $10.7 billion (Q1 2026), $11.1 billion (Q4 2025), and $11.6 billion (Q3 2025).

Peer Comparison